Immuneering updated investors on atebimetinib and progress in its Phase 3 MAPKeeper 301 study at the H.C. Wainwright conference. The company also pointed to earlier AACR data showing reduced tumor volume with preserved body mass and held one-on-one meetings.
published
Immuneering updated investors on atebimetinib and progress in its Phase 3 MAPKeeper 301 study at the H.C. Wainwright conference. The company also pointed to earlier AACR data showing reduced tumor volume with preserved body mass and held one-on-one meetings.
Latest documented BWB result
$APP market result
I Sold the $APP $310 Puts for Friday for $3 - been selling Puts on $APP every week with that hard floor of $300 and the high premium
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.